![Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo. - ppt download Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo. - ppt download](https://slideplayer.com/15976801/88/images/slide_1.jpg)
Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo. - ppt download
![Prevention Of Arterial And Venous Vascular Events In Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone - ISTH Congress Prevention Of Arterial And Venous Vascular Events In Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone - ISTH Congress](https://abstracts.isth.org/wp-content/uploads/2021/06/2242_results_1.png)
Prevention Of Arterial And Venous Vascular Events In Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone - ISTH Congress
Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS | PLOS ONE
![Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure | SpringerLink Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-019-00340-3/MediaObjects/13555_2019_340_Fig3_HTML.png)
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure | SpringerLink
![Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment | The Journal of Rheumatology Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment | The Journal of Rheumatology](https://www.jrheum.org/content/jrheum/46/1/7/F1.large.jpg)
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment | The Journal of Rheumatology
![Treatment-emergent adverse events per 100 patient-years by years of... | Download Scientific Diagram Treatment-emergent adverse events per 100 patient-years by years of... | Download Scientific Diagram](https://www.researchgate.net/publication/338721543/figure/fig2/AS:849953580658688@1579656133211/Treatment-emergent-adverse-events-per-100-patient-years-by-years-of-treatment-AE.png)
Treatment-emergent adverse events per 100 patient-years by years of... | Download Scientific Diagram
![Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events | Circulation: Cardiovascular Interventions Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events | Circulation: Cardiovascular Interventions](https://www.ahajournals.org/cms/asset/2b5b2d95-26ef-4fef-8ca2-a193f4186c37/circinterventions.121.011652.fig03.jpg)
Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events | Circulation: Cardiovascular Interventions
![Event rate per 100 patient-years of adverse clinical events for each... | Download Scientific Diagram Event rate per 100 patient-years of adverse clinical events for each... | Download Scientific Diagram](https://www.researchgate.net/publication/338482319/figure/fig2/AS:845458570223616@1578584439098/Event-rate-per-100-patient-years-of-adverse-clinical-events-for-each-renal-function.png)